Compositions for the treatment of fibrosis
US11707472B2 · kind B2 · utility
2Cited by
81References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2018 |
| Grant date | Jul 25, 2023 |
| Priority date | — |
| Expiry date | Jun 4, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.